Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 3
- Collinridge GL Peineau S Howland JG Wang YT Nat. Rev. Neurosci 2010 11 459 20559335
- 10.1016/0306-4522(95)00259-L · DOI · Paper page
- Machado-Vieira R Ibrahim L Henter ID Zarate CA Jr Pharmacol. Biochem. Behav 2012 100 678 21971560 PMC3253881 · DOI · Paper page
Cited by
Items 1,301–1,400 of 1,640
Synaptic plasticity in fronto-insular circuits underlying stress susceptibility and resilience
Rocks, D., & Liston, C. M. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.12.006 · Cited by 2
“…in depressed humans. e Postmortem histological analyses confirmed that synapse density and the expression of synapse-related genes are reduced in the prefrontal cortex, hippocampus, and nucleus accumbens of depressed patients (Duman and Aghajanian, 2012; Kang et al., 2012; Labonté et al., 2017).”
10.1016/b978-0-323-35944-3.00004-x
(2000) · Time to knit · doi:10.1016/b978-0-323-35944-3.00004-x · Cited by 1
Altered functional connectivity of thalamic subregions in premenstrual syndrome
Sun, R., Lai, Y., Zhang, Q., Chen, Y., Lai, Z., Duan, G., Wu, Y., Liu, Z., Zhang, Y., Li, S., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.038 · Cited by 1
Review of antidepressants and antipsychotics drugs: Trends, efficacy, and new directions
Mohammed, S. A., Al-Yassen, A. M., & Abbas, N. F. (2025) · International Journal of Pharmaceutical Sciences and Drug Analysis · doi:10.22271/27889246.2025.v5.i1b.111 · Cited by 2
Qiao, R., Liu, Y., Pu, J., Gui, S., Wang, D., Zhong, X., Chen, W., Chen, X., Chen, Y., Chen, X., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.05.005 · Cited by 2
Salih, S. K., Namiq, H. S., & Othman, H. H. (2025) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v9i1.2065 · Cited by 1
Höfels, S. (2025) · BILT Student Research Journal 2025 - Issue 6 · doi:10.70969/20251001
Zhong, J., Xiao, X., Liu, B., He, Z., Zhou, M., Zhou, E., & Hu, S. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07633-0 · Cited by 1
“This could indicate a hypo-functional state where synapses are structurally intact but functionally silenced, potentially through increased inhibi - tory neurotransmission or reduced neural firing [ 25].”
Vers une explication des effets mnémoniques des glucocorticoïdes ?
Jeanneteau, F. D. (2015) · médecine/sciences · doi:10.1051/medsci/20153104012 · Cited by 1
Braus, D. F. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0116-3 · Cited by 1
“Letztgenannte sind bei depressiven Störungen elementar gestört [7, 17].”
BackgroundNew Perspective on mTOR Pathways: A New Target of Depression
Réus, G. Z., Ignácio, Z. M., Abelaira, H. M., & Quevedo, J. (2017) · Springer eBooks · doi:10.1007/978-981-10-6580-4_8 · Cited by 2
Neurophysiologic Advance in Depressive Disorder
Xu, L., & Mao, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9271-0_5 · Cited by 1
Effects of Lithium on Brain Structure in Bipolar Disorder
Kaur, J., Kafantaris, V., & Szeszko, P. R. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.018 · Cited by 1
Case-Control and Cohort Designs
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.008 · Cited by 2
Null Hypothesis Significance Testing
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.014 · Cited by 1
Disfunção neuroquímica na depressão periparto
Rosa, C. E. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2017.tde-27072016-151947 · Cited by 1
Short but Continuous Natural Pain for Depression Treatment and BeyondPreprint
Huang, M. (2018) · Preprints.org · doi:10.20944/preprints201805.0411.v2
“Multiple factors that influence the function of the immune and nervous systems, such as monoamines and neural synapses, can be the triggering factors that initiate the development of depression (5, 30, 36, 37, 51).”
BackgroundShort but Continuous Natural Pain during Meditation Sittings for Depression Treatment: A Case ReportPreprint
Huang, M. (2018) · Preprints.org · doi:10.20944/preprints201805.0451.v1 · Cited by 1
Li, W., Ali, T., He, K., Liu, Z., Shah, F. A., Ren, Q., Jiang, A., Liu, Y., & Li, S. (2020) · Research Square · doi:10.21203/rs.3.rs-31118/v1 · Cited by 1
The Interactive Effects of Ketamine and Magnesium Upon Depressive-like Pathology
Razmjou, S. (2014) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2014-10484 · Cited by 1
Wei, S., Wang, F., Liu, J., & Wang, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.983604 · Cited by 2
Jász, A., Bíró, L., Buday, Z., Király, B., Szalárdy, O., Horváth, K., Komlósi, G., Bódizs, R., Kovács, K., Diana, M. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.20.537629 · Cited by 1
Yamamoto, H., Araki, S., Onodera, R., Go, Y., & Abe, K. (2023) · bioRxiv · doi:10.1101/2023.11.30.569491 · Cited by 1
Ketamine potentiates a central glutamatergic presynapsePreprint
Eshra, A., Lipstein, N., & Hallermann, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.17.571741 · Cited by 2
Tang, Y. C., Zhu, P., Luo, Y., Li, Y., Tang, J., Liu, L., Deng, Y., Li, J., Jiang, L. H., Yang, W., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4754030/v1 · Cited by 1
Pyramidal cell types and 5-HT 2A receptors are essential for psilocybin’s lasting drug actionPreprint
Shao, L.-X., Liao, C., Davoudian, P. A., Savalia, N. K., Jiang, Q., Wojtasiewicz, C., Tan, D., Nothnagel, J. D., Liu, R., Woodburn, S. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.02.621692 · Cited by 1
Autres toxicomanies (haschich, solvant, LSD)
Laqueille, X., Cohen, J., & Pflieger, C. (2014) · Time to knit · doi:10.1016/s0246-1072(14)53059-3 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
KETAMINE THERAPY IN A PATIENT WITH TREATMENT-RESISTANT BIPOLAR DEPRESSION: A CASE REPORT
Krastev, S. K., Bataklieva, S., Tacheva, S., Temelkov, A., Vladimirova, R., Stoyanova, V., & Milanova, V. (2013) · Meditsinski Pregled / Medical Review
Neurobiologic Foundations of Mood Disorders
Polan, H. J., Duman, R. S., & Schatzberg, A. F. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch21
Self-citationInvestigation of ketamine pharmacological modulation of aggressive behavior in adult zebrafish
(2016) · Neuroscience Communications · doi:10.14800/nc.1025
“However, in recent years, studies have reported the antidepressant potential of ketamine, which produces fast and robust effect on depressive patients resistant to conventional treatment ([2]).”
BackgroundMs Phillips and Dr Blier Reply
Phillips, J. L., & Blier, P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12lr08004a
PET Quantification in Neuropsychiatry
Koole, M. J. B., Casteels, C., & Laere, K. V. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_2 · Cited by 1
The E ffec t of Ketamine on Motor Coordination and The rmal Nociception in Ethanol-Withdrawn Mice
Ford, J. (2014) · DigitalCommons (California Polytechnic State University)
Phillips, J. L. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-2800
“Ketamine has faster effects on synaptic density relative to typical antidepressants which suggests the importance of synaptic alterations on treatment response in patients (Duman and Aghajanian, 2012).”
BackgroundMaking neurons from stem cells: Molecular mechanisms and spider silk substrates
Lewicka, M. (2013) · Figshare
Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior
Ballard, E. D., Richards, E. M., Ionescu, D. F., Niciu, M. J., Voort, J. V., & Zarate, C. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-09964-4_12
Запорожан, В. М., Подолський, В. В., & Хомінська, З. Б. (2014) · Reproductive Endocrinology · doi:10.18370/2309-4117.2014.17.9-13
Synapse- and cell-specific plasticity in the mature hippocampus
Queenan, B. N. (2014) · DigitalGeorgetown (Georgetown University Library)
ACMDCouncil on the Misuse of Drugs
Sulaiman, Z., Street, M., & Featherstone, L. (2014)
Oncodynamic Effect of Cancer on Depression
Nashed, M. G., Frey, B. N., Rosebush, P. I., & Singh, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-28558-0_6
Molz, S., & Ludka, F. K. (2016) · DRd - Desenvolvimento Regional em debate · doi:10.24302/drd.v6i2.1211 · Cited by 6
Mechanisms of NMDA receptor inhibition by memantine and ketamine
Glasgow, N. G. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Chronotherapeutics in Bipolar and Major Depressive Disorders: Implications for Novel Therapeutics
Duncan, W. C. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_7
宋, 杉., Wang, T., 孔, 莺., 汪, 容., 胡, 伟., 刘, 娟., 李, 胜., & 马, 一. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00084
Yusta, G., Díaz-Peláez, E., & Muriel, C. (2007) · PubMed
Circadian Mechanisms Underlying
Neurophysiology, R.-R., & McClung, C. A. (2016)
The Rise of Ketamine in Clinical Practice
Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180314-02
Short but Continuous Natural Pain during Meditation Sittings for Depression Treatment: A Case ReportPreprint
Huang, M. (2018) · Preprints.org · doi:10.20944/preprints201805.0451.v2
Prowse, N. A. (2017) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2017-12052
“Both the MAPK and PI3K pathways have been implicated in depression (Duman and Aghajanian, 2012), with activation of these pathways increasing synaptic protein transcription and translation, and receptor trafficking to the cell membrane (Minichiello, 2009).”
BackgroundEnvolvimento do óxido nítrico na metilação do DNA induzida por estresse
Maciel, I. D. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-25072018-094208
Diniz, C. R. A. F. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2018.tde-25052018-165247
Зайка, Т. О., Евдокимов, Д. В., & Абрамец, И. И. (2018) · Research Results in Pharmacology · doi:10.3897/rrpharmacology.4.29946
“These atrophic changes are manifested in a decreased volume of pyramidal neurons, a reduced dendritic branching, a decreased number of dendritic spines and, consequently, synapses, and a decreased volume of the cortex and limbic structures (Duman and Aghajanian 2012; Savitz and Drevets 2009).”
BackgroundAdvances in Neuroscience: Implications for Stress
Everly, G. S., & Lating, J. M. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9098-6_3
Strain, J. J. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-75659-7.00004-9
うつ病・不安障害におけるサーチュインの役割と創薬への 可能性
内田, 周. (2018) · 日本生物学的精神医学会誌 = Japanese journal of biological psychiatry · doi:10.11249/jsbpjjpp.29.2_69
Examining a Hypothyroid Model of Depressive Symptoms in Mice: Tests of Behavioral Measures
Ovadia, H. (2019) · Cited by 1
Serotonin receptor 4 in mature excitatory hippocampal neurons modulates mood and anxietyPreprint
Karayol, R., Medrihan, L., Warner-Schmidt, J., Rao, M., Holzner, E., Greengard, P., Heintz, N., & Schmidt, E. F. (2019) · bioRxiv · doi:10.1101/758151
Specific Effectiveness of Acupuncture and Kampo Medicine on Mice with Depression
Nishimura, K. (2020) · Journal of Complementary Medicine & Alternative Healthcare · doi:10.19080/jcmah.2020.11.555803
Antidepressants: current mechanisms and new hopes
Greener, M. (2014) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2014.3.1.23 · Cited by 1
Kang, M. J. Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00002-2 · Cited by 1
Sun, Y. (2017) · TSpace (University of Toronto)
Cognitive dysfunction in mice lacking proper glucocorticoid receptor dimerization
Looveren, K. V., Boxelaere, M. V., Callaerts‐Vegh, Z., & Libert, C. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.8.2
Абрамец, И. И., Евдокимов, Д. В., Кузнецов, Ю. В., & Сидорова, Ю. В. (2020) · Университетская клиника · doi:10.26435/uc.v0i3(36).559
Imaging Genetic and Epigenetic Markers in Mood Disorders
Poletti, S., Mazza, E. A., Vai, B., & Benedetti, F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.012
Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders
Kumar, P., Jiang, Y., & Whitton, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.006
Resting-State Functional Connectivity in Unipolar Depression
Chen, Z., & Gong, Q. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.007
Brain Imaging Methods in Mood Disorders
Selvaraj, S., Brambilla, P., & Soares, J. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.002
Kious, B. M., & Renshaw, P. F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.009
Neuroimaging Brain Inflammation in Mood Disorders
Meyer, J. H. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.011
Brain Imaging and the Mechanisms of Antidepressant Action
Godlewska, B. R., Selvaraj, S., & Cowen, P. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.020 · Cited by 1
Functional Near-Infrared Spectroscopy Studies in Mood Disorders
Matsuo, K., & Matsubara, T. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.014
Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus
Arnone, D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.003
Neuroimaging Biomarkers in Pediatric Mood Disorders
West, M. P., Tang, W. J., & Singh, M. K. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.005
fMRI Neurofeedback as Treatment for Depression
Skottnik, L., & Linden, D. E. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.013
Functional Connectome in Bipolar Disorder
Cha, J., & Anand, A. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.008 · Cited by 1
Neuroanatomical Findings in Bipolar Disorder
Tronchin, G., & McDonald, C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.004
Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders
Scotti-Muzzi, E., Otaduy, M. C. G., Soeiro‐de‐Souza, M. G., & Machado‐Vieira, R. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.010
Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder
Jauhar, S. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.019
Magnetoencephalography Studies in Mood Disorders
Nugent, A. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.016
The impact of external stress factors on hippocampus volume during antidepressant treatment
Hrtánek, I., Bittšanský, M., Tonhajzerová, I., Grendár, M., Oppa, M., Cesnekova, D., Farský, I., Hutka, P., Dobrota, D., Zeleňák, K., et al. (2021) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2020.12.004
Antidepressant-like effects and mechanisms of the herbal formula Xiaochaihutang in depression
Zhang, K., Yang, J., & Wu, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817935-2.00006-4 · Cited by 1
Oxytocin and Social Sensitivity: Implications for Vulnerability to Stress and Depressive Symptoms
McQuaid, R. J. (2015) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2015-11083
Interaction between perineuronal nets and ketamine in antidepressant actionPreprint
Young, C. K., Kinley, K. G., & McNaughton, N. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.30.446326
Rossi, G. N. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-08022021-150020
Thériault, R.-K. (2021) · The Atrium (University of Guelph) · doi:10.1503/jpn.200117 · Cited by 1
Bicaudal-C protein, a potential antidepressant target
Han, Q., Jiang, J., Yuan, Y., Tang, B., & Zhang, J. (2021) · Neuroreport · doi:10.1097/wnr.0000000000001729
Behavioural and molecular effects induced by Cannabidiol in animal models of depression
Silote, G. P. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2021.tde-29092021-060118
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.001
Construct and Data-Evaluation Validity
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.004
Single-Case Experimental Research Designs
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.009
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.007
Cautions, Negative Effects, and Replication
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.016
Selecting Measures for Research
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.011
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.021
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.013
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.022
Ideas that Begin the Research Process
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.005
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.